Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

Adil Daud(Memorial Sloan Kettering Cancer Center), Omid Hamid(Memorial Sloan Kettering Cancer Center)

Journal of Clinical Oncology

October 11, 2016

10.1200/jco.2016.67.2477

Cited by 674

Related Papers

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

|Journal of Clinical Investigation|2016|526

Supplementary data1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

|Unknown|2025|0